{"id":"https://openalex.org/W4249430952","doi":"https://doi.org/10.1200/jco.2009.27.18s.cra501","title":"Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced breast cancer","display_name":"Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced breast cancer","publication_year":2009,"publication_date":"2009-06-20","ids":{"openalex":"https://openalex.org/W4249430952","doi":"https://doi.org/10.1200/jco.2009.27.18s.cra501"},"language":"en","primary_location":{"id":"doi:10.1200/jco.2009.27.18s.cra501","doi":"https://doi.org/10.1200/jco.2009.27.18s.cra501","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2009.27.18s.cra501","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5087121536","display_name":"Andrew N.J. Tutt","orcid":"https://orcid.org/0000-0001-8715-2901","observed_orcids":["https://orcid.org/0000-0001-8715-2901"]},"institutions":[{"id":"https://openalex.org/I1298207432","display_name":"Guy's Hospital","ror":"https://ror.org/04r33pf22","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I1298207432","https://openalex.org/I200166805","https://openalex.org/I4210111135"]},{"id":"https://openalex.org/I1334819555","display_name":"Memorial Sloan Kettering Cancer Center","ror":"https://ror.org/02yrq0923","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1334819555"]},{"id":"https://openalex.org/I183935753","display_name":"King's College London","ror":"https://ror.org/0220mzb33","country_code":"GB","type":"education","lineage":["https://openalex.org/I124357947","https://openalex.org/I183935753"]},{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]},{"id":"https://openalex.org/I79576946","display_name":"University of Pennsylvania","ror":"https://ror.org/00b30xv10","country_code":"US","type":"education","lineage":["https://openalex.org/I79576946"]}],"countries":["GB","US"],"is_corresponding":false,"raw_author_name":"A. Tutt","raw_affiliation_strings":["Breakthrough Breast Cancer Research Unit, Kings College London School of Medicine, Guy's Hospital, London, United Kingdom; Memorial Sloan-Kettering Cancer Center, New York, NY; Dana-Farber Cancer Institute, Boston, MA; University of Pennsylvania, Philadelphia, PA; Cedars-Sinai Outpatient Cancer Center, Los Angeles, CA; City of Hope Comprehensive Cancer Center, Duarte, CA; Prince of Wales Cancer Centre, Sydney, Australia; AstraZeneca, Macclesfield, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Breakthrough Breast Cancer Research Unit, Kings College London School of Medicine, Guy's Hospital, London, United Kingdom; Memorial Sloan-Kettering Cancer Center, New York, NY; Dana-Farber Cancer Institute, Boston, MA; University of Pennsylvania, Philadelphia, PA; Cedars-Sinai Outpatient Cancer Center, Los Angeles, CA; City of Hope Comprehensive Cancer Center, Duarte, CA; Prince of Wales Cancer Centre, Sydney, Australia; AstraZeneca, Macclesfield, United Kingdom","institution_ids":["https://openalex.org/I1298207432","https://openalex.org/I1334819555","https://openalex.org/I183935753","https://openalex.org/I4210117453","https://openalex.org/I79576946"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5045514288","display_name":"Mark E. Robson","orcid":"https://orcid.org/0000-0002-3109-1692","observed_orcids":["https://orcid.org/0000-0002-3109-1692"]},"institutions":[{"id":"https://openalex.org/I1298207432","display_name":"Guy's Hospital","ror":"https://ror.org/04r33pf22","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I1298207432","https://openalex.org/I200166805","https://openalex.org/I4210111135"]},{"id":"https://openalex.org/I1334819555","display_name":"Memorial Sloan Kettering Cancer Center","ror":"https://ror.org/02yrq0923","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1334819555"]},{"id":"https://openalex.org/I183935753","display_name":"King's College London","ror":"https://ror.org/0220mzb33","country_code":"GB","type":"education","lineage":["https://openalex.org/I124357947","https://openalex.org/I183935753"]},{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]},{"id":"https://openalex.org/I79576946","display_name":"University of Pennsylvania","ror":"https://ror.org/00b30xv10","country_code":"US","type":"education","lineage":["https://openalex.org/I79576946"]}],"countries":["GB","US"],"is_corresponding":false,"raw_author_name":"M. Robson","raw_affiliation_strings":["Breakthrough Breast Cancer Research Unit, Kings College London School of Medicine, Guy's Hospital, London, United Kingdom; Memorial Sloan-Kettering Cancer Center, New York, NY; Dana-Farber Cancer Institute, Boston, MA; University of Pennsylvania, Philadelphia, PA; Cedars-Sinai Outpatient Cancer Center, Los Angeles, CA; City of Hope Comprehensive Cancer Center, Duarte, CA; Prince of Wales Cancer Centre, Sydney, Australia; AstraZeneca, Macclesfield, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Breakthrough Breast Cancer Research Unit, Kings College London School of Medicine, Guy's Hospital, London, United Kingdom; Memorial Sloan-Kettering Cancer Center, New York, NY; Dana-Farber Cancer Institute, Boston, MA; University of Pennsylvania, Philadelphia, PA; Cedars-Sinai Outpatient Cancer Center, Los Angeles, CA; City of Hope Comprehensive Cancer Center, Duarte, CA; Prince of Wales Cancer Centre, Sydney, Australia; AstraZeneca, Macclesfield, United Kingdom","institution_ids":["https://openalex.org/I1298207432","https://openalex.org/I1334819555","https://openalex.org/I183935753","https://openalex.org/I4210117453","https://openalex.org/I79576946"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5005206482","display_name":"Judy Ellen Garber","orcid":"https://orcid.org/0000-0001-9449-3982","observed_orcids":["https://orcid.org/0000-0001-9449-3982"]},"institutions":[{"id":"https://openalex.org/I1298207432","display_name":"Guy's Hospital","ror":"https://ror.org/04r33pf22","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I1298207432","https://openalex.org/I200166805","https://openalex.org/I4210111135"]},{"id":"https://openalex.org/I1334819555","display_name":"Memorial Sloan Kettering Cancer Center","ror":"https://ror.org/02yrq0923","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1334819555"]},{"id":"https://openalex.org/I183935753","display_name":"King's College London","ror":"https://ror.org/0220mzb33","country_code":"GB","type":"education","lineage":["https://openalex.org/I124357947","https://openalex.org/I183935753"]},{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]},{"id":"https://openalex.org/I79576946","display_name":"University of Pennsylvania","ror":"https://ror.org/00b30xv10","country_code":"US","type":"education","lineage":["https://openalex.org/I79576946"]}],"countries":["GB","US"],"is_corresponding":false,"raw_author_name":"J. E. Garber","raw_affiliation_strings":["Breakthrough Breast Cancer Research Unit, Kings College London School of Medicine, Guy's Hospital, London, United Kingdom; Memorial Sloan-Kettering Cancer Center, New York, NY; Dana-Farber Cancer Institute, Boston, MA; University of Pennsylvania, Philadelphia, PA; Cedars-Sinai Outpatient Cancer Center, Los Angeles, CA; City of Hope Comprehensive Cancer Center, Duarte, CA; Prince of Wales Cancer Centre, Sydney, Australia; AstraZeneca, Macclesfield, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Breakthrough Breast Cancer Research Unit, Kings College London School of Medicine, Guy's Hospital, London, United Kingdom; Memorial Sloan-Kettering Cancer Center, New York, NY; Dana-Farber Cancer Institute, Boston, MA; University of Pennsylvania, Philadelphia, PA; Cedars-Sinai Outpatient Cancer Center, Los Angeles, CA; City of Hope Comprehensive Cancer Center, Duarte, CA; Prince of Wales Cancer Centre, Sydney, Australia; AstraZeneca, Macclesfield, United Kingdom","institution_ids":["https://openalex.org/I1298207432","https://openalex.org/I1334819555","https://openalex.org/I183935753","https://openalex.org/I4210117453","https://openalex.org/I79576946"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5072480797","display_name":"S. M. Domchek","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1298207432","display_name":"Guy's Hospital","ror":"https://ror.org/04r33pf22","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I1298207432","https://openalex.org/I200166805","https://openalex.org/I4210111135"]},{"id":"https://openalex.org/I1334819555","display_name":"Memorial Sloan Kettering Cancer Center","ror":"https://ror.org/02yrq0923","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1334819555"]},{"id":"https://openalex.org/I183935753","display_name":"King's College London","ror":"https://ror.org/0220mzb33","country_code":"GB","type":"education","lineage":["https://openalex.org/I124357947","https://openalex.org/I183935753"]},{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]},{"id":"https://openalex.org/I79576946","display_name":"University of Pennsylvania","ror":"https://ror.org/00b30xv10","country_code":"US","type":"education","lineage":["https://openalex.org/I79576946"]}],"countries":["GB","US"],"is_corresponding":false,"raw_author_name":"S. Domchek","raw_affiliation_strings":["Breakthrough Breast Cancer Research Unit, Kings College London School of Medicine, Guy's Hospital, London, United Kingdom; Memorial Sloan-Kettering Cancer Center, New York, NY; Dana-Farber Cancer Institute, Boston, MA; University of Pennsylvania, Philadelphia, PA; Cedars-Sinai Outpatient Cancer Center, Los Angeles, CA; City of Hope Comprehensive Cancer Center, Duarte, CA; Prince of Wales Cancer Centre, Sydney, Australia; AstraZeneca, Macclesfield, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Breakthrough Breast Cancer Research Unit, Kings College London School of Medicine, Guy's Hospital, London, United Kingdom; Memorial Sloan-Kettering Cancer Center, New York, NY; Dana-Farber Cancer Institute, Boston, MA; University of Pennsylvania, Philadelphia, PA; Cedars-Sinai Outpatient Cancer Center, Los Angeles, CA; City of Hope Comprehensive Cancer Center, Duarte, CA; Prince of Wales Cancer Centre, Sydney, Australia; AstraZeneca, Macclesfield, United Kingdom","institution_ids":["https://openalex.org/I1298207432","https://openalex.org/I1334819555","https://openalex.org/I183935753","https://openalex.org/I4210117453","https://openalex.org/I79576946"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5060195943","display_name":"M. William Audeh","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1298207432","display_name":"Guy's Hospital","ror":"https://ror.org/04r33pf22","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I1298207432","https://openalex.org/I200166805","https://openalex.org/I4210111135"]},{"id":"https://openalex.org/I1334819555","display_name":"Memorial Sloan Kettering Cancer Center","ror":"https://ror.org/02yrq0923","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1334819555"]},{"id":"https://openalex.org/I183935753","display_name":"King's College London","ror":"https://ror.org/0220mzb33","country_code":"GB","type":"education","lineage":["https://openalex.org/I124357947","https://openalex.org/I183935753"]},{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]},{"id":"https://openalex.org/I79576946","display_name":"University of Pennsylvania","ror":"https://ror.org/00b30xv10","country_code":"US","type":"education","lineage":["https://openalex.org/I79576946"]}],"countries":["GB","US"],"is_corresponding":false,"raw_author_name":"M. W. Audeh","raw_affiliation_strings":["Breakthrough Breast Cancer Research Unit, Kings College London School of Medicine, Guy's Hospital, London, United Kingdom; Memorial Sloan-Kettering Cancer Center, New York, NY; Dana-Farber Cancer Institute, Boston, MA; University of Pennsylvania, Philadelphia, PA; Cedars-Sinai Outpatient Cancer Center, Los Angeles, CA; City of Hope Comprehensive Cancer Center, Duarte, CA; Prince of Wales Cancer Centre, Sydney, Australia; AstraZeneca, Macclesfield, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Breakthrough Breast Cancer Research Unit, Kings College London School of Medicine, Guy's Hospital, London, United Kingdom; Memorial Sloan-Kettering Cancer Center, New York, NY; Dana-Farber Cancer Institute, Boston, MA; University of Pennsylvania, Philadelphia, PA; Cedars-Sinai Outpatient Cancer Center, Los Angeles, CA; City of Hope Comprehensive Cancer Center, Duarte, CA; Prince of Wales Cancer Centre, Sydney, Australia; AstraZeneca, Macclesfield, United Kingdom","institution_ids":["https://openalex.org/I1298207432","https://openalex.org/I1334819555","https://openalex.org/I183935753","https://openalex.org/I4210117453","https://openalex.org/I79576946"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5029960276","display_name":"Jeffrey N. Weitzel","orcid":"https://orcid.org/0000-0001-6714-092X","observed_orcids":["https://orcid.org/0000-0001-6714-092X"]},"institutions":[{"id":"https://openalex.org/I1298207432","display_name":"Guy's Hospital","ror":"https://ror.org/04r33pf22","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I1298207432","https://openalex.org/I200166805","https://openalex.org/I4210111135"]},{"id":"https://openalex.org/I1334819555","display_name":"Memorial Sloan Kettering Cancer Center","ror":"https://ror.org/02yrq0923","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1334819555"]},{"id":"https://openalex.org/I183935753","display_name":"King's College London","ror":"https://ror.org/0220mzb33","country_code":"GB","type":"education","lineage":["https://openalex.org/I124357947","https://openalex.org/I183935753"]},{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]},{"id":"https://openalex.org/I79576946","display_name":"University of Pennsylvania","ror":"https://ror.org/00b30xv10","country_code":"US","type":"education","lineage":["https://openalex.org/I79576946"]}],"countries":["GB","US"],"is_corresponding":false,"raw_author_name":"J. N. Weitzel","raw_affiliation_strings":["Breakthrough Breast Cancer Research Unit, Kings College London School of Medicine, Guy's Hospital, London, United Kingdom; Memorial Sloan-Kettering Cancer Center, New York, NY; Dana-Farber Cancer Institute, Boston, MA; University of Pennsylvania, Philadelphia, PA; Cedars-Sinai Outpatient Cancer Center, Los Angeles, CA; City of Hope Comprehensive Cancer Center, Duarte, CA; Prince of Wales Cancer Centre, Sydney, Australia; AstraZeneca, Macclesfield, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Breakthrough Breast Cancer Research Unit, Kings College London School of Medicine, Guy's Hospital, London, United Kingdom; Memorial Sloan-Kettering Cancer Center, New York, NY; Dana-Farber Cancer Institute, Boston, MA; University of Pennsylvania, Philadelphia, PA; Cedars-Sinai Outpatient Cancer Center, Los Angeles, CA; City of Hope Comprehensive Cancer Center, Duarte, CA; Prince of Wales Cancer Centre, Sydney, Australia; AstraZeneca, Macclesfield, United Kingdom","institution_ids":["https://openalex.org/I1298207432","https://openalex.org/I1334819555","https://openalex.org/I183935753","https://openalex.org/I4210117453","https://openalex.org/I79576946"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5021894535","display_name":"Michael Leonard Friedlander","orcid":"https://orcid.org/0000-0003-3090-795X","observed_orcids":["https://orcid.org/0000-0003-3090-795X"]},"institutions":[{"id":"https://openalex.org/I1298207432","display_name":"Guy's Hospital","ror":"https://ror.org/04r33pf22","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I1298207432","https://openalex.org/I200166805","https://openalex.org/I4210111135"]},{"id":"https://openalex.org/I1334819555","display_name":"Memorial Sloan Kettering Cancer Center","ror":"https://ror.org/02yrq0923","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1334819555"]},{"id":"https://openalex.org/I183935753","display_name":"King's College London","ror":"https://ror.org/0220mzb33","country_code":"GB","type":"education","lineage":["https://openalex.org/I124357947","https://openalex.org/I183935753"]},{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]},{"id":"https://openalex.org/I79576946","display_name":"University of Pennsylvania","ror":"https://ror.org/00b30xv10","country_code":"US","type":"education","lineage":["https://openalex.org/I79576946"]}],"countries":["GB","US"],"is_corresponding":false,"raw_author_name":"M. Friedlander","raw_affiliation_strings":["Breakthrough Breast Cancer Research Unit, Kings College London School of Medicine, Guy's Hospital, London, United Kingdom; Memorial Sloan-Kettering Cancer Center, New York, NY; Dana-Farber Cancer Institute, Boston, MA; University of Pennsylvania, Philadelphia, PA; Cedars-Sinai Outpatient Cancer Center, Los Angeles, CA; City of Hope Comprehensive Cancer Center, Duarte, CA; Prince of Wales Cancer Centre, Sydney, Australia; AstraZeneca, Macclesfield, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Breakthrough Breast Cancer Research Unit, Kings College London School of Medicine, Guy's Hospital, London, United Kingdom; Memorial Sloan-Kettering Cancer Center, New York, NY; Dana-Farber Cancer Institute, Boston, MA; University of Pennsylvania, Philadelphia, PA; Cedars-Sinai Outpatient Cancer Center, Los Angeles, CA; City of Hope Comprehensive Cancer Center, Duarte, CA; Prince of Wales Cancer Centre, Sydney, Australia; AstraZeneca, Macclesfield, United Kingdom","institution_ids":["https://openalex.org/I1298207432","https://openalex.org/I1334819555","https://openalex.org/I183935753","https://openalex.org/I4210117453","https://openalex.org/I79576946"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5109315492","display_name":"J. Carmichael","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1298207432","display_name":"Guy's Hospital","ror":"https://ror.org/04r33pf22","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I1298207432","https://openalex.org/I200166805","https://openalex.org/I4210111135"]},{"id":"https://openalex.org/I1334819555","display_name":"Memorial Sloan Kettering Cancer Center","ror":"https://ror.org/02yrq0923","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1334819555"]},{"id":"https://openalex.org/I183935753","display_name":"King's College London","ror":"https://ror.org/0220mzb33","country_code":"GB","type":"education","lineage":["https://openalex.org/I124357947","https://openalex.org/I183935753"]},{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]},{"id":"https://openalex.org/I79576946","display_name":"University of Pennsylvania","ror":"https://ror.org/00b30xv10","country_code":"US","type":"education","lineage":["https://openalex.org/I79576946"]}],"countries":["GB","US"],"is_corresponding":false,"raw_author_name":"J. Carmichael","raw_affiliation_strings":["Breakthrough Breast Cancer Research Unit, Kings College London School of Medicine, Guy's Hospital, London, United Kingdom; Memorial Sloan-Kettering Cancer Center, New York, NY; Dana-Farber Cancer Institute, Boston, MA; University of Pennsylvania, Philadelphia, PA; Cedars-Sinai Outpatient Cancer Center, Los Angeles, CA; City of Hope Comprehensive Cancer Center, Duarte, CA; Prince of Wales Cancer Centre, Sydney, Australia; AstraZeneca, Macclesfield, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Breakthrough Breast Cancer Research Unit, Kings College London School of Medicine, Guy's Hospital, London, United Kingdom; Memorial Sloan-Kettering Cancer Center, New York, NY; Dana-Farber Cancer Institute, Boston, MA; University of Pennsylvania, Philadelphia, PA; Cedars-Sinai Outpatient Cancer Center, Los Angeles, CA; City of Hope Comprehensive Cancer Center, Duarte, CA; Prince of Wales Cancer Centre, Sydney, Australia; AstraZeneca, Macclesfield, United Kingdom","institution_ids":["https://openalex.org/I1298207432","https://openalex.org/I1334819555","https://openalex.org/I183935753","https://openalex.org/I4210117453","https://openalex.org/I79576946"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":5,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":24,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"27","issue":"18S","first_page":"CRA501","last_page":"CRA501"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11914","display_name":"PARP inhibition in cancer therapy","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11914","display_name":"PARP inhibition in cancer therapy","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10769","display_name":"BRCA gene mutations in cancer","score":0.00019999999494757503,"subfield":{"id":"https://openalex.org/subfields/1311","display_name":"Genetics"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T12829","display_name":"Advanced Breast Cancer Therapies","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/olaparib","display_name":"olaparib","score":0.9990000128746033},{"id":"https://openalex.org/keywords/parp-inhibitors","display_name":"PARP inhibitors","score":0.8379999995231628},{"id":"https://openalex.org/keywords/brca1-mutation","display_name":"BRCA1 mutation","score":0.8420000076293945},{"id":"https://openalex.org/keywords/brca2-mutation","display_name":"BRCA2 mutation","score":1.0},{"id":"https://openalex.org/keywords/advanced-breast-cancer","display_name":"advanced breast cancer","score":0.8100000023841858},{"id":"https://openalex.org/keywords/synthetic-lethality","display_name":"synthetic lethality","score":0.8220000267028809},{"id":"https://openalex.org/keywords/objective-response-rate","display_name":"objective response rate","score":0.7580000162124634},{"id":"https://openalex.org/keywords/progression-free-survival","display_name":"progression-free survival","score":0.9039999842643738},{"id":"https://openalex.org/keywords/adverse-events","display_name":"adverse events","score":0.6209999918937683},{"id":"https://openalex.org/keywords/fatigue","display_name":"fatigue","score":0.5099999904632568},{"id":"https://openalex.org/keywords/nausea","display_name":"nausea","score":0.5040000081062317},{"id":"https://openalex.org/keywords/anemia","display_name":"anemia","score":0.8650000095367432},{"id":"https://openalex.org/keywords/dose-reduction","display_name":"dose reduction","score":0.38999998569488525},{"id":"https://openalex.org/keywords/parp-inhibitor-resistance","display_name":"PARP inhibitor resistance","score":0.40400001406669617},{"id":"https://openalex.org/keywords/germline-mutation-carriers","display_name":"germline mutation carriers","score":0.47099998593330383}],"concepts":[{"id":"https://openalex.org/C2779962180","wikidata":"https://www.wikidata.org/wiki/Q7083106","display_name":"Olaparib","level":5,"score":0.9395207166671753},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9019171595573425},{"id":"https://openalex.org/C2778375690","wikidata":"https://www.wikidata.org/wiki/Q7814214","display_name":"Tolerability","level":3,"score":0.851586103439331},{"id":"https://openalex.org/C2779138821","wikidata":"https://www.wikidata.org/wiki/Q7118227","display_name":"PARP inhibitor","level":5,"score":0.7168670892715454},{"id":"https://openalex.org/C203092338","wikidata":"https://www.wikidata.org/wiki/Q1340863","display_name":"Clinical endpoint","level":3,"score":0.6621449589729309},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6373139023780823},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.6253064870834351},{"id":"https://openalex.org/C2780194787","wikidata":"https://www.wikidata.org/wiki/Q4836333","display_name":"BRCA mutation","level":4,"score":0.6218467950820923},{"id":"https://openalex.org/C530470458","wikidata":"https://www.wikidata.org/wiki/Q128581","display_name":"Breast cancer","level":3,"score":0.5509178638458252},{"id":"https://openalex.org/C2908647359","wikidata":"https://www.wikidata.org/wiki/Q2625603","display_name":"Population","level":2,"score":0.5099152326583862},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.508319079875946},{"id":"https://openalex.org/C31760486","wikidata":"https://www.wikidata.org/wiki/Q7180990","display_name":"Phases of clinical research","level":3,"score":0.48535266518592834},{"id":"https://openalex.org/C2779984678","wikidata":"https://www.wikidata.org/wiki/Q2145898","display_name":"Response Evaluation Criteria in Solid Tumors","level":4,"score":0.4372623562812805},{"id":"https://openalex.org/C2780427987","wikidata":"https://www.wikidata.org/wiki/Q172341","display_name":"Ovarian cancer","level":3,"score":0.4369763135910034},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.4113369286060333},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.3960125148296356},{"id":"https://openalex.org/C182979987","wikidata":"https://www.wikidata.org/wiki/Q3907241","display_name":"Poly ADP ribose polymerase","level":4,"score":0.060748398303985596},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.0},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.0},{"id":"https://openalex.org/C99454951","wikidata":"https://www.wikidata.org/wiki/Q932068","display_name":"Environmental health","level":1,"score":0.0},{"id":"https://openalex.org/C104317684","wikidata":"https://www.wikidata.org/wiki/Q7187","display_name":"Gene","level":2,"score":0.0},{"id":"https://openalex.org/C82381507","wikidata":"https://www.wikidata.org/wiki/Q416878","display_name":"Polymerase","level":3,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1200/jco.2009.27.18s.cra501","doi":"https://doi.org/10.1200/jco.2009.27.18s.cra501","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2009.27.18s.cra501","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":1.0}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W1906314377","https://openalex.org/W3093265161","https://openalex.org/W2110017381","https://openalex.org/W2147071985","https://openalex.org/W2409685183","https://openalex.org/W2117964602","https://openalex.org/W2946870784","https://openalex.org/W2600792505","https://openalex.org/W2071478061","https://openalex.org/W2199466904"],"abstract_inverted_index":{"CRA501":[0],"Background:":[1],"Olaparib":[2,294],"(AZD2281;":[3],"KU-0059436)":[4],"is":[5,299],"a":[6,119,179,343],"novel,":[7],"orally":[8],"active":[9,304],"PARP":[10,122],"inhibitor":[11],"that":[12,318],"induces":[13],"synthetic":[14],"lethality":[15],"in":[16,40,61,79,101,233,261,280,305,312,321,328],"homozygous":[17],"BRCA-deficient":[18,41,308,329],"cells.":[19],"A":[20],"phase":[21,89],"I":[22],"trial":[23],"identified":[24,121],"400":[25,108,195,296],"mg":[26,109,117,196,224,284,297],"bd":[27,110,197,285,298],"as":[28],"the":[29,57,106,281],"maximum":[30],"tolerated":[31,301],"dose":[32,124],"(MTD)":[33],"with":[34,65,265,326],"an":[35,84],"initial":[36],"signal":[37],"of":[38,51,59,181,185,207,335,342,368],"efficacy":[39,58,141],"ovarian":[42],"cancers":[43,331],"(ASCO":[44],"2008;":[45],"abst":[46],"5510).":[47],"The":[48,70,139,213],"primary":[49,140],"aim":[50,72],"this":[52,80],"study":[53,325],"was":[54,73,143,220,228,315],"to":[55,74,178,317],"test":[56],"olaparib":[60,100,327],"confirmed":[62,130],"BRCA1/BRCA2":[63,131,313],"carriers":[64,314],"advanced":[66,306],"refractory":[67],"breast":[68,137,309,330],"cancer.":[69,138,310],"secondary":[71,160],"assess":[75],"safety":[76],"and":[77,113,133,155,201,205,248,272,302,340],"tolerability":[78,341],"population.":[81],"Methods:":[82],"In":[83],"international,":[85],"multicenter,":[86],"proof-of-concept,":[87],"single-arm,":[88],"II":[90],"study,":[91],"two":[92],"sequential":[93],"patient":[94],"(pt)":[95],"cohorts":[96],"received":[97],"continuous":[98],"oral":[99],"28-day":[102],"cycles":[103],"initially":[104],"at":[105,115,194,295],"MTD,":[107],"(27":[111,125],"pts),":[112,268,271],"subsequently":[114],"100":[116,283],"bd,":[118],"previously":[120,320],"inhibitory":[123],"pts).":[126],"Eligibility":[127],"criteria":[128],"included":[129],"mutation":[132],"recurrent,":[134],"measurable":[135],"chemotherapy-refractory":[136,307],"endpoint":[142],"best":[144],"objective":[145],"response":[146],"rate":[147,158],"(ORR;":[148],"RECIST)":[149],"post":[150],"baseline.":[151],"Progression-free":[152],"survival":[153],"(PFS)":[154],"clinical":[156],"benefit":[157],"were":[159,165,192,259,278],"endpoints.":[161],"All":[162],"adverse":[163],"events":[164],"reported":[166,319],"using":[167],"CTCAE":[168],"v3.":[169],"Results:":[170],"On":[171],"November":[172],"20,":[173],"2008,":[174],"54":[175],"pts":[176,191,236,263,277],"exposed":[177],"median":[180],"three":[182],"prior":[183],"lines":[184],"chemotherapy":[186],"had":[187,209,238,242,246,251],"been":[188],"enrolled.":[189],"27":[190,276],"dosed":[193],"(18":[198],"BRCA1":[199],"deficient":[200],"9":[202],"BRCA2":[203],"deficient),":[204],"24":[206],"these":[208],"databased":[210],"RECIST":[211],"assessments.":[212],"ORR":[214],"(currently":[215],"based":[216],"on":[217],"unconfirmed":[218],"responses)":[219],"38%":[221],"(9/24)":[222],"(400":[223],"bd).":[225],"Causally-related":[226,253],"toxicity":[227],"mainly":[229],"mild":[230],"(grade":[231],"1\u20132)":[232],"severity;":[234],"9/27":[235],"(33%)":[237],"fatigue;":[239],"7/27":[240],"(26%)":[241],"nausea;":[243],"4/27":[244],"(15%)":[245],"vomiting;":[247],"1/27":[249],"(4%)":[250],"anemia.":[252],"grade":[254],"3":[255],"or":[256,351,354],"higher":[257],"toxicities":[258],"seen":[260],"5":[262],"(19%)":[264],"fatigue":[266],"(3":[267],"nausea":[269],"(2":[270],"anemia":[273],"(1":[274],"pt).":[275],"treated":[279],"subsequent":[282],"cohort":[286],"where":[287],"no":[288],"data":[289],"are":[290],"currently":[291],"available.":[292],"Conclusions:":[293],"well":[300],"highly":[303],"Toxicity":[311],"similar":[316],"non-carriers.":[322],"This":[323],"first":[324],"provides":[332],"positive":[333],"proof":[334],"concept":[336],"for":[337],"high":[338],"activity":[339],"genetically":[344],"defined":[345],"targeted":[346],"therapy.":[347],"Author":[348],"Disclosure":[349],"Employment":[350],"Leadership":[352],"Consultant":[353],"Advisory":[355],"Role":[356],"Stock":[357],"Ownership":[358],"Honoraria":[359],"Research":[360,370],"Funding":[361],"Expert":[362],"Testimony":[363],"Other":[364],"Remuneration":[365],"AstraZeneca,":[366,375],"Institute":[367],"Cancer":[369],"AstraZeneca":[371,372],"Myriad":[373],"Genetics":[374],"Kudos":[376]},"counts_by_year":[{"year":2016,"cited_by_count":1},{"year":2013,"cited_by_count":1},{"year":2012,"cited_by_count":1}],"updated_date":"2026-10-01T08:54:57.152042","created_date":"2022-05-12T00:00:00"}